-
1
-
-
84872016068
-
Therapeutic effects of PPARα agonists on diabetic retinopathy in type 1 diabetes models
-
Chen Y, Hu Y, Lin M, et al. Therapeutic effects of PPARα agonists on diabetic retinopathy in type 1 diabetes models. Diabetes 2013;62:261-272
-
(2013)
Diabetes
, vol.62
, pp. 261-272
-
-
Chen, Y.1
Hu, Y.2
Lin, M.3
-
2
-
-
42449121829
-
Effect of glycemic exposure on the risk of microvascular complications in the Diabetes Control and Complications Trial-revisited
-
Lachin JM, Genuth S, Nathan DM, Zinman B, Rutledge BN. Effect of glycemic exposure on the risk of microvascular complications in the Diabetes Control and Complications Trial-revisited. Diabetes 2008;57:995-1001
-
(2008)
Diabetes
, vol.57
, pp. 995-1001
-
-
Lachin, J.M.1
Genuth, S.2
Nathan, D.M.3
Zinman, B.4
Rutledge, B.N.5
-
3
-
-
82755165018
-
Intensive glycaemic control for patients with type 2 diabetes: Systematic review with meta-analysis and trial sequential analysis of randomised clinical trials
-
Hemmingsen B, Lund SS, Gluud C, et al. Intensive glycaemic control for patients with type 2 diabetes: systematic review with meta-analysis and trial sequential analysis of randomised clinical trials. BMJ 2011;343:d6898
-
(2011)
BMJ
, vol.343
-
-
Hemmingsen, B.1
Lund, S.S.2
Gluud, C.3
-
4
-
-
79959494229
-
Recent advances in the treatment of atherogenic dyslipidemia in type 2 diabetes mellitus
-
Wanner C, Krane V. Recent advances in the treatment of atherogenic dyslipidemia in type 2 diabetes mellitus. Kidney Blood Press Res 2011;34:209-217
-
(2011)
Kidney Blood Press Res
, vol.34
, pp. 209-217
-
-
Wanner, C.1
Krane, V.2
-
5
-
-
77954051832
-
Fenofibrate and metabolic syndrome
-
Kraja AT, Province MA, Straka RJ, Ordovas JM, Borecki IB, Arnett DK. Fenofibrate and metabolic syndrome. Endocr Metab Immune Disord Drug Targets 2010;10:138-148
-
(2010)
Endocr Metab Immune Disord Drug Targets
, vol.10
, pp. 138-148
-
-
Kraja, A.T.1
Province, M.A.2
Straka, R.J.3
Ordovas, J.M.4
Borecki, I.B.5
Arnett, D.K.6
-
6
-
-
77954654472
-
Effects of medical therapies on retinopathy progression in type 2 diabetes
-
Chew EY, Ambrosius WT, Davis MD, et al. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med 2010;363:233-244
-
(2010)
N Engl J Med
, vol.363
, pp. 233-244
-
-
Chew, E.Y.1
Ambrosius, W.T.2
Davis, M.D.3
-
7
-
-
36049001784
-
Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): A randomised controlled trial
-
DOI 10.1016/S0140-6736(07)61607-9, PII S0140673607616079
-
Keech AC, Mitchell P, Summanen PA, et al.; FIELD study investigators. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet 2007;370:1687-1697 (Pubitemid 350100775)
-
(2007)
Lancet
, vol.370
, Issue.9600
, pp. 1687-1697
-
-
Keech, A.1
Mitchell, P.2
Summanen, P.3
O'Day, J.4
Davis, T.5
Moffitt, M.6
Taskinen, M.-R.7
Simes, R.8
Tse, D.9
Williamson, E.10
Merrifield, A.11
Laatikainen, L.12
D'Emden, M.13
Crimet, D.14
O'Connell, R.15
Colman, P.16
-
8
-
-
84862734043
-
Fenofibrate - A potential systemic treatment for diabetic retinopathy?
-
Wong TY, Simó R, Mitchell P. Fenofibrate - a potential systemic treatment for diabetic retinopathy? Am J Ophthalmol 2012;154:6-12
-
(2012)
Am J Ophthalmol
, vol.154
, pp. 6-12
-
-
Wong, T.Y.1
Simó, R.2
Mitchell, P.3
-
9
-
-
79960462692
-
Medical management of diabetic retinopathy: Fenofibrate and ACCORD eye studies
-
Lond
-
Wright AD, Dodson PM. Medical management of diabetic retinopathy: fenofibrate and ACCORD eye studies. Eye (Lond) 2011;25:843-849
-
(2011)
Eye
, vol.25
, pp. 843-849
-
-
Wright, A.D.1
Dodson, P.M.2
-
11
-
-
68549107838
-
Peroxisome-proliferator-activated receptor-alpha activation protects brain capillary endothelial cells from oxygen-glucose deprivation-induced hyperpermeability in the blood-brain barrier
-
Mysiorek C, Culot M, Dehouck L, et al. Peroxisome-proliferator-activated receptor-alpha activation protects brain capillary endothelial cells from oxygen-glucose deprivation-induced hyperpermeability in the blood-brain barrier. Curr Neurovasc Res 2009;6:181-193
-
(2009)
Curr Neurovasc Res
, vol.6
, pp. 181-193
-
-
Mysiorek, C.1
Culot, M.2
Dehouck, L.3
-
12
-
-
68349142979
-
Fenofibrate attenuates endothelial monocyte adhesion in chronic heart failure: An in vitro study
-
Huang WP, Yin WH, Chen JW, Jen HL, Young MS, Lin SJ. Fenofibrate attenuates endothelial monocyte adhesion in chronic heart failure: an in vitro study. Eur J Clin Invest 2009;39:775-783
-
(2009)
Eur J Clin Invest
, vol.39
, pp. 775-783
-
-
Huang, W.P.1
Yin, W.H.2
Chen, J.W.3
Jen, H.L.4
Young, M.S.5
Lin, S.J.6
-
13
-
-
41149095864
-
PPARalpha activators upregulate eNOS activity and inhibit cytokine-induced NF-kappaB activation through AMP-activated protein kinase activation
-
Okayasu T, Tomizawa A, Suzuki K, Manaka K, Hattori Y. PPARalpha activators upregulate eNOS activity and inhibit cytokine-induced NF-kappaB activation through AMP-activated protein kinase activation. Life Sci 2008;82:884-891
-
(2008)
Life Sci
, vol.82
, pp. 884-891
-
-
Okayasu, T.1
Tomizawa, A.2
Suzuki, K.3
Manaka, K.4
Hattori, Y.5
-
14
-
-
0037168869
-
PPARalpha and PPARdelta activators inhibit cytokine-induced nuclear translocation of NF-kappaB and expression of VCAM-1 in EAhy926 endothelial cells
-
DOI 10.1016/S0014-2999(01)01589-8, PII S0014299901015898
-
Rival Y, Benéteau N, Taillandier T, et al. PPARalpha and PPARdelta activators inhibit cytokine-induced nuclear translocation of NF-kappaB and expression of VCAM-1 in EAhy926 endothelial cells. Eur J Pharmacol 2002;435:143-151 (Pubitemid 34131694)
-
(2002)
European Journal of Pharmacology
, vol.435
, Issue.2-3
, pp. 143-151
-
-
Rival, Y.1
Beneteau, N.2
Taillandier, T.3
Pezet, M.4
Dupont-Passelaigue, E.5
Patoiseau, J.-F.6
Junquero, D.7
Colpaert, F.C.8
Delhon, A.9
-
15
-
-
85047684089
-
PPARkappa and GR differentially down-regulate the expression of nuclear factor-kappaB-responsive genes in vascular endothelial cells
-
DOI 10.1210/en.142.8.3332
-
Xu X, Otsuki M, Saito H, et al. PPARalpha and GR differentially downregulate the expression of nuclear factor-kappaB-responsive genes in vascular endothelial cells. Endocrinology 2001;142:3332-3339 (Pubitemid 32681737)
-
(2001)
Endocrinology
, vol.142
, Issue.8
, pp. 3332-3339
-
-
Xu, X.1
Otsuki, M.2
Saito, H.3
Sumitani, S.4
Yamamoto, H.5
Asanuma, N.6
Kouhara, H.7
Kasayama, S.8
-
16
-
-
18444371741
-
PPAR activators inhibit endothelial cell migration by targeting Akt
-
DOI 10.1016/S0006-291X(02)00385-6, PII S0006291X02003856
-
Goetze S, Eilers F, Bungenstock A, et al. PPAR activators inhibit endothelial cell migration by targeting Akt. Biochem Biophys Res Commun 2002;293:1431-1437 (Pubitemid 34681037)
-
(2002)
Biochemical and Biophysical Research Communications
, vol.293
, Issue.5
, pp. 1431-1437
-
-
Goetze, S.1
Eilers, F.2
Bungenstock, A.3
Kintscher, U.4
Stawowy, P.5
Blaschke, F.6
Graf, K.7
Law, R.E.8
Fleck, E.9
Grafe, M.10
-
17
-
-
1242297567
-
PPARalpha Activators Inhibit Vascular Endothelial Growth Factor Receptor-2 Expression by Repressing Sp1-Dependent DNA Binding and Transactivation
-
DOI 10.1161/01.RES.0000113781.08139.81
-
Meissner M, Stein M, Urbich C, et al. PPARalpha activators inhibit vascular endothelial growth factor receptor-2 expression by repressing Sp1-dependent DNA binding and transactivation. Circ Res 2004;94:324-332 (Pubitemid 38240723)
-
(2004)
Circulation Research
, vol.94
, Issue.3
, pp. 324-332
-
-
Meissner, M.1
Stein, M.2
Urbich, C.3
Reisinger, K.4
Suske, G.5
Staels, B.6
Kaufmann, R.7
Gille, J.8
-
18
-
-
79952986434
-
Fenofibrate suppresses microvascular inflammation and apoptosis through adenosine monophosphate-activated protein kinase activation
-
Tomizawa A, Hattori Y, Inoue T, Hattori S, Kasai K. Fenofibrate suppresses microvascular inflammation and apoptosis through adenosine monophosphate-activated protein kinase activation. Metabolism 2011;60:513-522
-
(2011)
Metabolism
, vol.60
, pp. 513-522
-
-
Tomizawa, A.1
Hattori, Y.2
Inoue, T.3
Hattori, S.4
Kasai, K.5
-
19
-
-
38949145780
-
PPARalpha agonist fenofibrate suppresses tumor growth through direct and indirect angiogenesis inhibition
-
DOI 10.1073/pnas.0711281105
-
Panigrahy D, Kaipainen A, Huang S, et al. PPARalpha agonist fenofibrate suppresses tumor growth through direct and indirect angiogenesis inhibition. Proc Natl Acad Sci USA 2008;105:985-990 (Pubitemid 351282068)
-
(2008)
Proceedings of the National Academy of Sciences of the United States of America
, vol.105
, Issue.3
, pp. 985-990
-
-
Panigrahy, D.1
Kaipainen, A.2
Huang, S.3
Butterfield, C.E.4
Barnes, C.M.5
Fannon, M.6
Laforme, A.M.7
Chaponis, D.M.8
Folkman, J.9
Kieran, M.W.10
-
20
-
-
34247108235
-
Fenofibrate regulates retinal endothelial cell survival through the AMPK signal transduction pathway
-
DOI 10.1016/j.exer.2007.01.009, PII S0014483507000310
-
Kim J, Ahn JH, Kim JH, et al. Fenofibrate regulates retinal endothelial cell survival through the AMPK signal transduction pathway. Exp Eye Res 2007;84:886-893 (Pubitemid 46590130)
-
(2007)
Experimental Eye Research
, vol.84
, Issue.5
, pp. 886-893
-
-
Kim, J.1
Ahn, J.-H.2
Kim, J.-H.3
Yu, Y.-S.4
Kim, H.-S.5
Ha, J.6
Shinn, S.-H.7
Oh, Y.-S.8
-
21
-
-
0141960109
-
AMP-activated protein kinase activity is critical for hypoxia-inducible factor-1 transcriptional activity and its target gene expression under hypoxic conditions in DU145 cells
-
DOI 10.1074/jbc.M306104200
-
Lee M, Hwang JT, Lee HJ, et al. AMP-activated protein kinase activity is critical for hypoxia-inducible factor-1 transcriptional activity and its target gene expression under hypoxic conditions in DU145 cells. J Biol Chem 2003;278:39653-39661 (Pubitemid 37248526)
-
(2003)
Journal of Biological Chemistry
, vol.278
, Issue.41
, pp. 39653-39661
-
-
Lee, M.1
Hwang, J.-T.2
Lee, H.-J.3
Jung, S.-N.4
Kang, I.5
Chi, S.-G.6
Kim, S.-S.7
Ha, J.8
|